Parnell Jacob M, Fazili Irtiqa, Bloch Sarah C, Lacy D Borden, Garcia-Lopez Valeria A, Bernard Rachel, Skaar Eric P, Edwards Kathryn M, Nicholson Maribeth R
Department of Medicine, Vanderbilt University Medical Center, Nashville.
University of Tennessee Health Science Center, Memphis.
J Pediatr Gastroenterol Nutr. 2021 Mar 1;72(3):378-383. doi: 10.1097/MPG.0000000000002944.
Recent Infectious Disease Society of America guidelines recommend multistep testing algorithms to diagnose Clostridioides difficile infection (CDI), including a combination of nucleic acid amplification-based testing (NAAT) and toxin enzyme immunoassay (EIA). The use of these algorithms in children, including the ability to differentiate between C. difficile colonization and CDI, however, has not been evaluated.
We prospectively enrolled asymptomatic pediatric patients with cancer, cystic fibrosis (CF), or inflammatory bowel disease (IBD) and obtained a stool sample for NAAT testing. If positive by NAAT (colonized), EIA was performed. In addition, children with symptomatic CDI who tested positive by NAAT via the clinical laboratory were enrolled, and EIA was performed on residual stool. A functional cell cytotoxicity neutralization assay (CCNA) was also applied to stool samples from both the colonized and symptomatic cohorts.
Of the 225 asymptomatic children enrolled in the study, 47 (21%) were colonized with C. difficile including 9/59 (15.5%) with cancer, 30/92 (32.6%) with CF, and 8/74 (10.8%) with IBD. An additional 41 children with symptomatic CDI were enrolled. When symptomatic and colonized children were compared, neither EIA positivity (44% vs 26%, P = 0.07) nor CCNA positivity (49% vs 45%, P = 0.70) differed significantly or were able to predict disease severity in the symptomatic cohort.
Use of a multistep testing algorithm with NAAT followed by EIA failed to differentiate symptomatic CDI from asymptomatic colonization in our pediatric cohort. As multistep algorithms are moved into clinical care, the pediatric provider will need to be aware of their limitations.
美国传染病学会近期发布的指南推荐采用多步骤检测算法来诊断艰难梭菌感染(CDI),包括基于核酸扩增的检测(NAAT)和毒素酶免疫测定(EIA)相结合的方法。然而,这些算法在儿童中的应用,包括区分艰难梭菌定植和CDI的能力,尚未得到评估。
我们前瞻性纳入了患有癌症、囊性纤维化(CF)或炎症性肠病(IBD)的无症状儿科患者,并获取粪便样本进行NAAT检测。如果NAAT检测呈阳性(定植),则进行EIA检测。此外,纳入通过临床实验室NAAT检测呈阳性的有症状CDI儿童,并对剩余粪便进行EIA检测。还对定植和有症状队列的粪便样本应用了功能性细胞毒性中和试验(CCNA)。
在纳入研究的225名无症状儿童中,47名(21%)被艰难梭菌定植,其中包括9/59名(15.5%)癌症患儿、30/92名(32.6%)CF患儿和8/74名(10.8%)IBD患儿。另外纳入了41名有症状CDI儿童。比较有症状和定植儿童时,EIA阳性率(44%对26%,P = 0.07)和CCNA阳性率(49%对45%,P = 0.70)均无显著差异,也无法预测有症状队列中的疾病严重程度。
在我们的儿科队列中,采用先NAAT后EIA的多步骤检测算法未能区分有症状CDI和无症状定植。随着多步骤算法应用于临床护理,儿科医疗服务提供者需要意识到其局限性。